{"preliminary_commentary":{"by_channel":{"x_thread":5,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"TBCRC065","nct_id":"NCT06439693","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tbcrc065-nct06439693. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will complete:\n\n* Screening visit with tumor biopsy and imaging.\n* Imaging on Day I of cycles for Parts A through D.\n* Part A:\n\n  * Day 1 of 21 day cycle: Predetermined dose of Trastuzumab (or biosimilar) 1X daily\n  * Day 1 of 21 day cycle: Predetermined dose of Pertuzumab 1X daily\n  * Predetermined dose of Taxane (Paclitaxel, Docetaxel, or Nab-Paclitaxel)\n* Part B:\n\n  --Day 1 of 21 day cycle: Predetermined dose of trastuzumab deruxtecan 1X daily\n* Part C:\n\n  * Day 1 of 21 day cycle: Predetermined dose of T-DM1 1X daily\n  * Days 1 through 21 of 21 day cycle: Predetermined dose of Tucatinib 2X daily\n* Part D:\n* Imaging every 9 weeks\n\n  * Days 1 through 21 of 21 day cycle: Predetermined dose of Tucatinib 2X daily\n  * Day 1 of 21 day cycle: Predetermined dose of Trastuzumab (biosimilar or SC) 1X daily\n  * Day 1 of 21 day cycle: Predetermined dose of Pertuzumab (or PHESGO) 1X daily\n* Follow Up: visits every 12 weeks with imaging every 9 weeks.","label":"HER2+ Breast Cancer","type":"EXPERIMENTAL"}],"collaborators":["Translational Breast Cancer Research Consortium","Johns Hopkins University"],"completion_date":{"date":"2033-03-30","type":"ESTIMATED"},"conditions":["Breast Cancer Female","Breast Cancer","Breast Cancer Metastatic","Estrogen Receptor-positive Breast Cancer","HER2-positive Breast Cancer","Stage IV Breast Cancer"],"enrollment":{"count":72,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Nab-Paclitaxel","otherNames":["Abraxane","ABI-007","Albumin-bound paclitaxel"],"type":"DRUG"},{"name":"Paclitaxel","otherNames":["Taxol"],"type":"DRUG"},{"name":"Docetaxel","otherNames":["Taxotere"],"type":"DRUG"},{"name":"Phesgo","otherNames":["pertuzumab plus trastuzumab plus hyaluronidase-zzxf","RG6264","RO7198574"],"type":"DRUG"},{"name":"T-DM1","otherNames":["ado-trastuzumab emtansine","Kadcyla"],"type":"DRUG"},{"name":"Pertuzumab","otherNames":[],"type":"DRUG"},{"name":"Trastuzumab Deruxtecan","otherNames":["Enhertu","fam-trastuzumab deruxtecan-nxki","T-DXd","DS-8201a"],"type":"DRUG"},{"name":"Trastuzumab Subcutaneous Subcutaneous","otherNames":["Herceptin Hylecta","Trastuzumab and hyaluronidase-oysk"],"type":"DRUG"},{"name":"Tucatinib","otherNames":[],"type":"DRUG"},{"name":"Trastuzumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-06","lead_sponsor":"Dana-Farber Cancer Institute","official_title":"A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer: The SAPPHO Study","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2030-03-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease Free Survival at 4 Years (DFS4)","timeFrame":"Up to 4 years"}],"references":[],"start_date":{"date":"2024-08-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer","url":"https://clinicaltrials.gov/study/NCT06439693"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tbcrc065-nct06439693"}